Heart Health
SGLT2 Inhibitors Deliver Far More Than Blood Sugar Control
A major review reveals how SGLT2 inhibitors protect the heart, kidneys, and metabolism through at least seven distinct biological mechanisms.
Research Paper
May 12, 2026 0
Results for "SGLT2 Inhibitors" in Heart Disease
20 articles
Heart Health
SGLT2 Inhibitors Cut Death and Heart Failure Risk Even in Patients Over 80
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
Research Paper
May 12, 2026 0
Heart Health
Dapagliflozin Targets Exercise Pressure and Heart Metabolism in HFpEF Trial
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
Clinical Trial
Jun 25, 2026 0
Heart Health
Premium
Vascular Rejuvenation: Advanced Interventions to Reverse Arterial Aging
Dive deep into the molecular mechanisms of vascular aging and explore cutting-edge interventions — from senolytic therapies and nitric oxide restoration to exercise-induced remodeling and emerging pharmacological approaches — that are redefining what's possible in cardiovascular longevity.
TutorialAdvanced
May 2, 2026 0
Heart Health
Oral Semaglutide Dramatically Improves Heart Health in High-Risk Diabetes Patients
New analysis reveals oral semaglutide significantly reduces cardiovascular risk factors beyond blood sugar control in type 2 diabetes.
Research Paper
Mar 28, 2026 2
Heart Health
GLP-1 Drugs Cut Death Risk 33% in Diabetics After Heart Attack
A new meta-analysis of 37,393 patients finds GLP-1 receptor agonists may reduce mortality and major cardiac events in type 2 diabetics with prior MI.
Review
Jul 2, 2026 0
Heart Health
GLP-1 Drugs Show Promise for Heart Protection Beyond Diabetes Treatment
New research reveals GLP-1 receptor agonists could significantly reduce cardiovascular risk in broader patient populations.
Research Paper
Mar 28, 2026 2
Heart Health
GLP-1 Medications May Work Effectively with Less Frequent Dosing
New research suggests GLP-1 drugs could maintain benefits with reduced dosing frequency, potentially improving convenience and adherence.
Research Paper
Mar 28, 2026 0
Heart Health
Oral GLP-1 Drug Orforglipron Slashes Blood Pressure, Cholesterol and Inflammation in Phase 2 Trials
A pill-form GLP-1 receptor agonist significantly reduced multiple cardiovascular risk markers in both T2D and obesity patients over 26–36 weeks.
Research Paper
Jun 4, 2026 0
Heart Health
Oral Semaglutide Shows Lasting Reductions in Cardiovascular Risk Factors
New evidence suggests oral semaglutide sustains long-term improvements in key CVD risk factors, expanding its role beyond diabetes management.
Research Paper
Apr 26, 2026 0
Heart Health
Oral GLP-1 Drugs Could Replace Weekly Injections for Weight Loss and Heart Health
New oral formulations of popular GLP-1 medications may eliminate the need for weekly injections while maintaining benefits.
Research Paper
Mar 28, 2026 0
Heart Health
Large VA Study Reveals What GLP-1 Drugs Actually Do to Your Pancreas
New VA database analysis sheds light on the contested link between GLP-1 receptor agonists and pancreatitis risk.
Video
Jun 26, 2026 0
Heart Health
GLP-1 Drugs Linked to Rising Pancreatitis Deaths Prompting New Safety Warning
Health authorities issue new warnings as reports of fatal pancreatitis cases increase among GLP-1 drug users.
Research Paper
Mar 29, 2026 2
Heart Health
Tirzepatide Outperforms Dulaglutide for Heart and Kidney Protection in Diabetes
Major study shows tirzepatide reduces cardiovascular and kidney complications by 16% compared to dulaglutide in diabetic patients.
Research Paper
Mar 30, 2026 0
Heart Health
Semaglutide Shows Promise for Alzheimer's Disease Treatment in New Research
GLP-1 drug semaglutide demonstrates potential benefits for Alzheimer's patients following major clinical trial results.
Research Paper
Mar 28, 2026 2
Heart Health
Tirzepatide Falls Short of Dulaglutide for Heart Protection in Type 2 Diabetes
New research shows tirzepatide doesn't surpass dulaglutide's cardiovascular benefits despite being a newer diabetes medication.
Research Paper
Mar 28, 2026 2
Heart Health
Over Half of Cardiology Patients May Qualify for Semaglutide Under New Guidelines
Real-world registry data shows 54% of coronary artery disease patients meet eligibility criteria for semaglutide based on SELECT and SOUL trial standards.
Research Paper
Jun 27, 2026 0
Heart Health
How Glucose and Ketones in Urine Reveal Hidden Metabolic Health Issues
Learn what glucose and ketones in your urine actually mean for your metabolic health and diabetes risk.
Video
Mar 28, 2026 0
Heart Health
GLP-1 Weight Loss Drugs Preserve Muscle Function Despite Minor Mass Loss
New research shows GLP-1 medications primarily burn fat while maintaining muscle strength and improving overall body composition.
Research Paper
Mar 28, 2026 1
Heart Health
Major Alzheimer's Drug Trial Fails: Semaglutide Shows No Cognitive Benefits
Large clinical trial finds popular diabetes drug semaglutide ineffective at slowing Alzheimer's progression in early-stage patients.
Research Paper
Mar 28, 2026 2
Heart Health
GLP-1 Drugs Cut Heart Failure and Death Risk 24–43% in Sleep Apnea Patients
A real-world study of 37,000+ matched patients finds GLP-1 receptor agonists dramatically reduce cardiovascular events in obese adults with OSA.
Research Paper
Jul 2, 2026 0
Page 1 of 2Next